Foods for Health Institute
Foods for Health Institute
Zivkovic A.M.,University of California at Davis |
Zivkovic A.M.,Foods for Health Institute |
Smilowitz J.T.,University of California at Davis |
Smilowitz J.T.,Foods for Health Institute |
And 2 more authors.
Food Science and Technology | Year: 2011
A number of researchers share their views regarding factors that have a significant impact on a more personalized approach to diet and health. They believe that diet and health will gradually become a personal knowledge management system in the same way as in many other existing complex human activities. Consumers need to be informed about their health status and to be confident that the steps that they are taking to improve it are working. The food industry needs to know that there are consumers with unmet needs for their particular products and that they can demonstrate in those consumers that their products are achieving the health goals that their products claim. Diet can also begin to act in a more pre-emptive manner in improving the health with a more personalized approach to health through measurement and guidance.
Zivkovic A.M.,University of California at Davis |
Telis N.,University of California at Davis |
German J.B.,Foods for Health Institute |
German J.B.,University of California at Davis |
Hammock B.D.,University of California at Davis
California Agriculture | Year: 2011
This article focuses on the role of omega-3 fatty acids as precursors for lipid signaling molecules known as oxylipins. Although omega-3 fatty acids are beneficial in autoimmune disorders, inflammatory diseases and heart disease, they are generally underrepre-sented in the American diet. A literature review confirms that the consumption of omega-3 fatty acids - whether in food sources such as walnuts, flax seeds and fatty fish (including salmon and sardines), or in supplements - is associated with decreased morbidity and mortality. This growing body of evidence, including the results of a recent study of patients with kidney disease, highlights the need to measure omega-3 fatty acids and their oxylipin products as markers of metabolic health and biomarkers of disease. In addition, there is substantial evidence of the need to increase the omega-3 fatty acid content of American diets to optimize metabolic health.
PubMed | Food Science &Technology and Foods for Health Institute
Type: | Journal: Scientific reports | Year: 2015
Breast milk enhances the predominance of Bifidobacterium species in the infant gut, probably due to its large concentration of human milk oligosaccharides (HMO). Here we screened infant-gut isolates of Bifidobacterium longum subsp. infantis and Bifidobacterium bifidum using individual HMO, and compared the global transcriptomes of representative isolates on major HMO by RNA-seq. While B. infantis displayed homogeneous HMO-utilization patterns, B. bifidum were more diverse and some strains did not use fucosyllactose (FL) or sialyllactose (SL). Transcriptomes of B. bifidum SC555 and B. infantis ATCC 15697 showed that utilization of pooled HMO is similar to neutral HMO, while transcriptomes for growth on FL were more similar to lactose than HMO in B. bifidum. Genes linked to HMO-utilization were upregulated by neutral HMO and SL, but not by FL in both species. In contrast, FL induced the expression of alternative gene clusters in B. infantis. Results also suggest that B. bifidum SC555 does not utilize fucose or sialic acid from HMO. Surprisingly, expression of orthologous genes differed between both bifidobacteria even when grown on identical substrates. This study highlights two major strategies found in Bifidobacterium species to process HMO, and presents detailed information on the close relationship between HMO and infant-gut bifidobacteria.
News Article | November 9, 2016
The First Microbiome-based Product for Newborn Foals Launches in December DAVIS, CA--(Marketwired - Nov 9, 2016) - Evolve BioSystems today announced plans to launch their first microbiome-based animal health product, GlycoGuard, at the American Association of Equine Practitioners national meeting in Orlando, Fla. on Dec. 3, 2016. GlycoGuard, the first oral activated microbial gel for newborn foals, is a combination of two activated beneficial bacteria, B. infantis and L. plantarum, which selectively thrive on mare's milk. When provided to nursing foals immediately after birth, GlycoGuard works along with mare's milk to properly establish the intestinal microflora during these important first few weeks of life. "We are thrilled to be launching the first in our line of animal health products, knowing the critical role the gut microbiome plays in the health of all newborns," says Evolve CEO, Dr. David Kyle. Protecting the Newborn Gut Microbiome Adding selective probiotic supplementation to the diet is a promising approach to modulate the gut microbiome, and may be especially effective in supporting gut health in nursing foals. B. infantis and L. plantarum are believed to work together with mare's milk in a three-part action to: consume and utilize the complex carbohydrates found in milk;produce short chain fatty acids which lower the pH of the lower intestine; and stabilize the gut tight-junction proteins. As a result, this develops a naturally healthy intestinal environment for the newborn and its microbiota. "Horse owners are acutely aware of the challenges involved in managing newborn intestinal health in their animals, but they have few options at their disposal," said Dr. Duane Maye, DVM, Director of Animal Health at Evolve BioSystems. "Through our extensive understanding of the relationship between mammalian milk and the newborn intestinal microbiome, we have developed a product that is not only easy to administer to foals, but it has a profound ability to promote and support the intestinal health of foals in a way that hasn't been demonstrated by any other product currently on the market." Evolve BioSystems recently concluded a clinical trial in high risk newborn thoroughbred foals, demonstrating the ability of GlycoGuard to support intestinal health in the midst of an infectious disease outbreak. The results of this trial are currently under consideration for peer-reviewed publication and expected to be available at the end of this year. About Evolve BioSystems Evolve BioSystems, Inc. is a privately held microbiome company dedicated to developing the next generation of products to establish, restore and maintain a healthy gut microbiome. Evolve is a spin-out from the Foods for Health Institute (FFHI) at the University of California at Davis and builds on more than a decade of research into understanding the unique partnership of the newborn gut microbiome and breast milk components. Having led to the discovery and development of products to resolve infant gut dysbiosis, Evolve's discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle, as well as in various animal species. Evolve completed a $9 million Series A capital raise in 2015 and has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering. In addition, Evolve is undertaking further clinical studies to build out its offering of microbiome-based solutions across a spectrum of unmet clinical needs. To learn more about GlycoGuard, please visit www.glycoguard.com For more information on Evolve BioSystems, please visit www.evolvebiosystems.com
Schaefer S.E.,Foods for Health Institute |
Camacho-Gomez R.,University of California |
Sadeghi B.,University of California |
Kaiser L.,University of California |
And 2 more authors.
Preventing Chronic Disease | Year: 2015
Introduction: In California's agricultural Central Valley, the rate of childhood obesity is higher than the national average. Adequate physical activity contributes to obesity prevention and its assessment is useful to evaluate the impact of interventions. Methods: Niños Sanos, Familia Sana (Healthy Children, Healthy Family [NSFS]) uses community-based participatory research to implement an intervention program to reduce childhood obesity among people of Mexican origin in the Central Valley. Anthropometric measurements were conducted on more than 650 children enrolled in NSFS. Physical activity data from a subgroup of children aged 4 to 7 years (n = 134) were collected via a wearable accelerometer. Results: Children were classified on the basis of age and sex-adjusted body mass index as healthy weight (57.7%); overweight (19.3%), or obese (23%). Logistic regression showed that moderate to vigorous physical activity (MVPA) was associated with a child's likelihood of having a healthy BMI (odds ratio: 1.03; 95% CI, 1.01-1.05; P = .017). Conclusion: NSFS's community-based participatory approach resulted in successful use of a commercial electronic device to measure physical activity quantity and quality in this hard-to-reach population. Promotion of adequate daily MVPA is an appropriate and necessary component of NSFS's childhood obesity prevention strategy.
News Article | November 18, 2016
DAVIS, CA--(Marketwired - Nov 17, 2016) - Evolve BioSystems, Inc., a microbiome company developing novel solutions to resolve gut dysbiosis, is pleased to announce that Susan Vandegrift has joined the executive team as Chief Financial Officer. As CFO of Evolve, Susan will bring senior level finance expertise to aid in the launch of the company's microbiome-based products into the global commercial marketplace. "Joining Evolve at this critical time in the company's development allows me to combine my expertise in commercializing CPG products along with rapidly scaling small businesses to become global leaders in the marketplace," says Vandegrift. In her previous role as an instrumental member of the early executive team at Rodan + Fields, Vandegrift leveraged transformational forces & disruptive technologies to grow the company into one of the largest and the fastest growing premium skincare brand in the United States. Infant gut dysbiosis is an unintended consequence of increasing rates of Cesarean section birth, formula feeding and excessive antibiotic use. This dysbiosis appears to be correlated with metabolic and inflammatory disruptions later in life including obesity, type I diabetes, atopy, food allergies, and asthma. The company's immediate focus is to commercialize products for newborn gut health, a unique offering based on the important and emerging field of microbiome science. "Susan brings both experience and passion to our mission. We are thrilled to add her to our executive management team, as we transition from feasibility and proof of concept, to a series of product launches across both human and animal health markets in the US and around the world," says Dr. David Kyle, Evolve's CEO. About Evolve BioSystems Evolve BioSystems, Inc. is a privately-held microbiome company dedicated to developing the next generation of products to establish, restore, and maintain a healthy gut microbiome. Evolve is a spin-out from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components. Having led to the discovery and development of products to resolve infant gut dysbiosis, Evolve's discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle as well as in various animal species. Evolve completed a $9 million Series A capital raise in 2015 and has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering. In addition, Evolve is undertaking further clinical studies to build out its offering of microbiome-based solutions across a spectrum of unmet clinical needs. For more information on Evolve BioSystems, please visit: www.evolvebiosystems.com
News Article | December 20, 2016
DAVIS, CA--(Marketwired - Dec 20, 2016) - Evolve BioSystems, Inc., a microbiome company developing novel solutions to resolve infant gut dysbiosis, is pleased to announce that the European Patent Office has upheld European Patent EP2405918, overcoming an opposition launched by infant formula manufacturer Danone. "This was a great win which further emphasizes the strength of our patent portfolio in the prebiotic/bifidobacteria space as it pertains to infant nutrition," said Dr. Samara Freeman, Evolve's Director of Intellectual Property. The main claims of EP2405918, issued to the Regents of the University of California and licensed to Evolve, relate to compositions and prophylactic and therapeutic uses of combinations of certain galactooligosaccharides (GOS) and key commensal species of bifidobacteria. Compositions covered by the invention include infant formulas, follow-on formulas, and toddler beverages. Similar versions of the patent have issued in the US (USP 8425930), Germany, France, and the UK. Dr. David Kyle, Chief Executive Officer of Evolve, stated, "We are pleased with the EPO's ruling, as it showcases the impact of our patent strategy. Going forward, the Company will continue to rigorously defend all of its intellectual property, and that licensed from the University of California, including taking enforcement action against any parties that employ Evolve's protected technology without permission." Dushyant Pathak, Associate Vice Chancellor of Research and Executive Director of Venture Catalyst at UC Davis, commented, "We are extremely pleased to see our patent rights providing the basis for a strong competitive position for UC Davis spin-out, Evolve BioSystems. I am particularly excited at the potential for Evolve's products to make a direct impact on healthy infant nutrition and development." Evolve BioSystems, Inc. is a privately-held microbiome company dedicated to developing the next generation of products to establish, restore, and maintain a healthy gut microbiome. Evolve is a spin-out from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components. Having led to the discovery and development of products to resolve infant gut dysbiosis, Evolve's discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle as well as in various animal species. Evolve has successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offerings. In addition, Evolve is undertaking further clinical studies to build out its suite of microbiome-based solutions. For more information on Evolve BioSystems, please visit: www.evolvebiosystems.com